Axsome Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
Mailing Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK, NY, 10007
Phone
(212) 332-3241
Fiscal Year End
1231
EIN
454241907
Financial Overview
FY2025
$322.93M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
Annual Reports
10-K
February 23, 2026
- Achieved profitability in 2023 with $55 million net income, a significant turnaround from a $180 million net loss in 2022.
- Total revenue surged to $480 million in 2023 from $120 million in 2022, driven by successful product launches AUVELITY® and SUNOSI®.
Insider Trading
STRONG SELL
6 insiders
13 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.